Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelinesBox 1. Clinical questions (1.1.3, 1.1.8, 1.2.4, 1.2.5)∗Box 2. Clinical question (4.1.1, 4.3.4)∗Box 3. Clinical questions (5.1.1–5.1.4)∗Box 4. Clinical questions (4.a.4a-d, 4.3.6, 4.3.7)∗
Background: Allergen immunotherapy (AIT) has a longstanding history and still remains the only disease-changing treatment for allergic rhinitis and asthma. Over the years 2 different schools have developed their strategies: the United States (US) and the European. Allergen extracts available in thes...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-08-01
|
Series: | World Allergy Organization Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455120303471 |